



T1D
Exchange

Data Governance Committee Meeting

February 12, 2026

Data Governance Meeting Agenda

1. Welcome
2. Chair Roles
3. Proposed projects
 - a) Teplizumab use in Stage 3 (will submit to Sanofi)
 - b) Qualitative surveys/focus groups on DMT (will submit Breakthrough T1D)
 - c) Older adults and AID use (will submit to ADA)
4. Discussion of future proposal ideas/interest
5. Next meeting schedule

Co-Chair Roles



DGC Co-Chair term will be ending in June 2026.

Thank you to Drs. Davis and Hansen for their committee leadership for the past two years!

Nominate yourself or a colleague:

https://t1d.iad1.qualtrics.com/jfe/form/SV_bHkuTLINZo1m6Xk

May meeting will be used as transition, for a warm hand off between the chairs.



Grant/funding/data opportunities

Stage 3 T1D and teplizumab treatment workflows

Potential for new Sanofi supported project to be proposed over the next 30-90 days related to operationalizing teplizumab treatment into early Stage 3 workflows. Predicated on labelling, etc.

*= currently available/tracked

Category	Metric	Notes
Screening and Baseline	Autoantibodies <ul style="list-style-type: none"> • Method* • Age at screening* • Dates Setting (research / clinic)* Other autoimmunity* Source of Referral* DKA at Stage 3 diagnosis*	Dates for stage 1, 2, 3 Family history or autoimmunity
Therapies	Therapy (yes/no) <ul style="list-style-type: none"> • Timing of discussion Type of Therapy* Timing related to Stage 3 diagnosis* Related labs* Protocol <ul style="list-style-type: none"> • Protocol used, any deviation • Inpatient vs home vs hybrid • Age at treatment • Side effects 	Reason declined if No Infections, CBC/CMP

Beta Cell	C-peptide Total Daily Dose of Insulin* (units/kg/day) Insulin dose adjusted HbA1c *	MMTT vs random vs after a home meal; standardize <0.25 units/kg/day HbA1c + (4*TDD)
Immunologic	Autoantibody number and type* Repeat testing	
Metabolic	Hemoglobin A1c (%)* CGM Metrics <ul style="list-style-type: none"> • TIR* • Time in Tight Range (TiTR, 70-140 mg/dL) • Time above 140 mg/dL (TA140) • TBR/hypoglycemia* • Glycemic variability - CV* 	>10% TA140 associated with high risk of progression to Stage 3 T1D within 1 year ¹²
Patient Centered	Race/ethnicity* Insurance* BMI* Psychosocial screening* DKA or severe hypoglycemia after DMT*	

Qualitative discussions on referring to DMT trials

1. Proposed project supported by Breakthrough T1D- qualitative focus groups and studies related to how clinics refer newly dx PWD/families into early Stage 3 trials to advance research on disease modifying therapies (DMT.)
2. Output for this could be a potential manuscript based on the new [qualitative] dataset.
3. Good alignment with existing Beta Cell Working Group plans.
4. Data use/data governance of an emerging data set for us: Stage 1, Stage 2, and newly dx Stage 3 diabetes. Much/most of the Stage 1-2 data would be migrating in from Primary Care or another source outside of Endocrinology.

Discussion of future proposal ideas/interest

1. Proposed project supported by Breakthrough T1D- qualitative focus groups and studies related to how clinics refer newly dx PWD/families into early Stage 3 trials.
2. Output for this could be a potential manuscript based on the new [qualitative] dataset.
3. Good alignment with existing Beta Cell Working Group plans.
4. Emerging data set for us: Stage 1, Stage 2, and newly dx Stage 3 diabetes. Much/most of the Stage 1-2 data would be migrating in from Primary Care or another source outside of Endocrinology.

AID use and older adults

- Potential for new ADA sponsored intervention, involving older adults and AID use.
- Planned as a small project- with just two centers participating.
- This could be an opportunity for us to discuss a dataset that we don't often analyze or benchmark: data on adults over the age of 65.

Proposal aims

- **Aim 1:** Characterize the determinants of AID use among older adults with T1D across patient, caregiver, provider, and system levels using qualitative methods.
- **Aim 2:** Select and test implementation strategies to increase AID use among older adults with T1D in three adult endocrinology clinics.
- **Aim 3:** Evaluate the effectiveness of the implementation strategies on AID adoption and clinical outcomes (diabetic ketoacidosis (DKA) and severe hypoglycemic events (SHE) in adult endocrinology clinics.

American Diabetes Association®

**Request for Applications: Innovative Research to Improve
the Lives of Older Adults Living with Diabetes**



Questions